Matinas BioPharma Holdings Inc Stock Other OTC
Equities
US5768101058
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
0.178 USD | 0.00% |
05-09 | Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 43.39M 59.11M |
---|---|---|---|---|---|
Net income 2024 * | -25M -34.06M | Net income 2025 * | -34M -46.32M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-1.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
Latest transcript on Matinas BioPharma Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 13-04-30 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 19-01-02 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 20-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 13-04-30 |
Natasha Giordano
BRD | Director/Board Member | 62 | 20-09-13 |
Eric Ende
CHM | Chairman | 55 | 17-04-02 |
1st Jan change | Capi. | |
---|---|---|
+8.69% | 114B | |
+10.47% | 104B | |
-12.64% | 22.41B | |
-0.44% | 22.28B | |
-5.80% | 19.07B | |
-37.36% | 18B | |
-5.49% | 17.89B | |
+6.79% | 14.28B | |
+36.52% | 12.55B |